Auxilium revenue outlook cut removes overhang, says Leerink Leerink believes Auxilium's revenue outlook reduction is not surprising since Testim prescriptions have been declining 26% annually and 16% compared to last quarter. The firm says the news removes an overhang on the stock and points out that Testim represents only $1 of its $36 price target for shares. Leerink keeps an Outperform rating on Auxilium.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.